MiRNA, a New Treatment Strategy for Pulmonary Fibrosis

Author(s): Yanhong Liu, Hongguang Nie*, Yan Ding, Yapeng Hou, Kejun Mao, Yong Cui

Journal Name: Current Drug Targets

Volume 22 , Issue 7 , 2021

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Pulmonary fibrosis (PF) is the most common chronic, progressive interstitial lung disease, mainly occurring in the elderly, with a median survival of 2-4 years after diagnosis. Its high mortality rate attributes to the delay in diagnosis due to its generic symptoms, and more importantly, to the lack of effective treatments. MicroRNAs (miRNAs) are a class of small non-coding RNAs that are involved in many essential cellular processes, including extracellular matrix remodeling, alveolar epithelial cell apoptosis, epithelial-mesenchymal transition, etc. We summarized the dysregulated miRNAs in TGF-β signaling pathway-mediated PF in recent years with dual effects, such as anti-fibrotic let-7 family and pro-fibrotic miR-21 members. Therefore, this review will set out the latest application of miRNAs to provide a new direction for PF treatment.

Keywords: Pulmonary fibrosis, microRNAs, transforming growth factor-β, extracellular matrix, epithelial-mesenchymal transition, pro-fibrotic.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2021
Published on: 28 September, 2020
Page: [793 - 802]
Pages: 10
DOI: 10.2174/1874609813666200928141822
Price: $65

Article Metrics

PDF: 34